Items where authors include "Eckert, L."

Export as [feed] Atom [feed] RSS
Number of items: 8.

Article

Silverberg, J.I., Simpson, E.L., Guttman-Yassky, E. et al. (15 more authors) (2021) Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis : a post hoc analysis of 5 randomized clinical trials. Dermatitis, 32 (1S). S81-S91. ISSN 1710-3568

Paller, A.S., Siegfried, E.C., Simpson, E.L. et al. (12 more authors) (2021) A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Journal of the European Academy of Dermatology and Venereology, 35 (2). pp. 464-475. ISSN 0926-9959

de Bruin-Weller, M., Simpson, E.L., Cork, M. orcid.org/0000-0003-4428-2428 et al. (6 more authors) (2020) Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. Journal of the American Academy of Dermatology, 83 (5). pp. 1499-1501. ISSN 0190-9622

Cork, M.J. orcid.org/0000-0003-4428-2428, Thaçi, D., Eichenfield, L.F. et al. (19 more authors) (2020) Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis : results from a phase IIa open‐label trial and subsequent phase III open‐label extension. British Journal of Dermatology, 182 (1). pp. 85-96. ISSN 0007-0963

Cork, M.J. orcid.org/0000-0003-4428-2428, Eckert, L., Simpson, E.L. et al. (14 more authors) (2019) Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment. ISSN 0954-6634

de Bruin-Weller, M., Thaçi, D., Smith, C.H. et al. (12 more authors) (2018) Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo‐controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). British Journal of Dermatology , 178 (5). pp. 1083-1101. ISSN 0007-0963

Simpson, E.L., Bieber, T., Guttman-Yassky, E. et al. (23 more authors) (2016) Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. The New England Journal of Medicine. ISSN 0028-4793

Proceedings Paper

Cork, M.J. orcid.org/0000-0003-4428-2428, Eichenfield, L.F., Blauvelt, A. et al. (9 more authors) (2019) 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis. In: Journal of Investigative Dermatology. Society for Investigative Dermatology (SID) 2019, 08-11 May 2019, Hilton Chicago, Chicago, Illinois. Elsevier , S104-S104.

This list was generated on Sat Apr 20 14:23:05 2024 BST.